JPMorgan assumed coverage of Surgery Partners (SGRY) with a Neutral rating and $27 price target The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners President Resigns Effective October 2025
- Surgery Partners Announces Credit Agreement Amendment
- Bank of America Sees 5 Market Drivers in Play — and Suggests 2 Stocks to Buy
- Surgery Partners Appoints New Chairman After Resignation
- Surgery Partners: Strategic Positioning and Financial Performance Drive Buy Rating Amid Macroeconomic Challenges